What were the results of the DAPA-HF study?
The DAPA-HF study demonstrated that among 4,744 patients with HFrEF, the risk of worsening HF or death from CV causes was lower among those who received dapagli ozin than among those who received placebo, regardless of the presence or absence of T2D (16.3% in the dapagli ozin group versus 21.2% in the placebo group; hazard ratio: 0.74; 95% CI: 0.65 to 0.85). In addition, dapagli ozin demonstrated a significant reduction in each of the individual components of the composite endpoint, with a 30% decrease in the risk of experiencing a first episode of worsening HF (hospitalization for HF/urgent HF visit) and an 18% decrease in the risk of CV death (12).